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Background:  Prevalence of heart failure with preserved ejection fraction (HFpEF) increases with age. Cardiac myosin binding protein-C 
(cMyBP-C), which is a heart muscle thick filament protein, can regulate cross-bridge attach/detachment process by its phosphorylation 
status. Thus, we hypothesize that phosphorylated cMyBP-C can enhance cardiac relaxation even with aging.
methods:  We aged three mouse models of wild-type equivalent cMyBP-C(tWT), phosphorylation deficient cMyBP-C(t3SA), and 
phosphorylation mimetic cMyBP-C(t3SD) to 1-year. The phosphorylation mimetic cMyBP-C(t3SD) hearts demonstrated enhanced diastolic 
function with fastest tissue Doppler of myocardial relaxation during early diastole e’ and smallest blood flow Doppler to e’ ratio (E/e’). 
Conversely, MyBPC3(t3SA) hearts showed diastolic dysfunction by largest E/e’ but normal EF. All models showed similarly negligible 
amount of fibrosis of less than 0.2% and similar blood pressures. Intact papillary muscle studies showed MyBPC3(t3SD) to have fastest 
relaxation kinetics despite similar calcium decay kinetics while MyBPC3(t3SA) behaved at the opposite extreme. Thus, phosphorylated 
MyBPC3 facilitating cross-bridge detachment is the likely mechanism.
conclusion:  Phosphorylated cMyBPC3 enhanced diastolic function despite aging by facilitating cross-bridge detachment; therefore, it can 
be a future target for treatment of HFpEF.
Echocardiography tWT, n=7 t3SA (↓Phos), n=5 t3SD (↓Phos), n=6
HR (beats/min) 428±17 391±19 413±11
EF (%) 53.6±4.2 49.6±1.2 50.2±1.2
e’ (mm/s) 24.7±3.1# 13.3±1.7*,# 33.1±2.8*
E/e’ 31.4±4# 39.6±5# 16±0.9*
Fibrosis tWT, n=3 t3SA (↓Phos), n=3 t3SD (↓Phos), n=3
0.096±0.041% 0.037±0.018% 0.028±0.005%
Blood Pressure (mmHg) tWT, n=5 t3SA (↓Phos), n=6 t3SD (↓Phos), n=5
103.0 ± 2.5 108.8 ± 2.3 102.6 ± 2.5
Intact Papillary Muscle paced at 2Hz tWT, n=8 t3SA (↓Phos), n=6 t3SD (↓Phos), n=8
kCa (calcium decay rate constant 1/s) 6.79±0.38 6.12±0.35 6.68±0.19
kforce (force decay rate costant 1/s) 16.56±1.13# 12.64±0.89*,# 20.98±1.22*
*p<0.05 vs. tWT; #p<0.05 vs.t3SD
